Dakota Wealth Management Purchases Shares of 5,921 Natera, Inc. $NTRA

Dakota Wealth Management purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,921 shares of the medical research company’s stock, valued at approximately $1,356,000.

A number of other hedge funds also recently modified their holdings of NTRA. JPMorgan Chase & Co. increased its holdings in Natera by 9.4% in the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after purchasing an additional 1,003,129 shares during the period. State Street Corp increased its stake in shares of Natera by 2.2% in the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after buying an additional 72,087 shares during the period. Franklin Resources Inc. raised its position in shares of Natera by 37.5% during the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after acquiring an additional 727,366 shares during the last quarter. Fred Alger Management LLC lifted its stake in shares of Natera by 1.7% in the third quarter. Fred Alger Management LLC now owns 2,451,779 shares of the medical research company’s stock worth $394,663,000 after acquiring an additional 41,303 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in Natera by 39.0% in the third quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock valued at $386,338,000 after acquiring an additional 673,315 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 85,299 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $230.72, for a total value of $19,680,185.28. Following the completion of the sale, the chief executive officer owned 127,881 shares of the company’s stock, valued at approximately $29,504,704.32. This trade represents a 40.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 23,205 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70. Following the sale, the insider owned 144,992 shares of the company’s stock, valued at approximately $34,035,422.08. This represents a 13.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 318,344 shares of company stock valued at $74,091,416 in the last 90 days. Corporate insiders own 5.63% of the company’s stock.

Natera Stock Down 6.9%

Shares of NASDAQ NTRA opened at $182.65 on Friday. The firm has a market cap of $25.89 billion, a PE ratio of -119.38 and a beta of 1.65. The company’s fifty day simple moving average is $211.01 and its 200 day simple moving average is $208.38. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.81. The firm had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. During the same period in the previous year, the firm posted ($0.41) earnings per share. On average, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NTRA. Morgan Stanley lowered their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Canaccord Genuity Group reaffirmed a “buy” rating on shares of Natera in a research report on Monday, January 12th. TD Cowen reissued a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. Finally, Wells Fargo & Company upped their target price on Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $253.47.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.